Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 4, 2001, Pages 216-222

  Alvarnas, Joseph C ^a,b   Linn, Yeh Ching ^a   Hope, Ernest G ^a   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b City Hope Samaritan Bone Marrow T   (United States)

Author keywords

Autologous transplantation; Cytotoxicity; Immunotherapy; NK T cells; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; BLAST CELL; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DONOR; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; KILLER CELL; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MALIGNANT NEOPLASTIC DISEASE; PERIPHERAL BLOOD STEM CELL; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE CARE; TARGET CELL; TREATMENT OUTCOME; TUMOR CELL;

EID: 0035031130     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11349808     Document Type: Article

References (31)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
3. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
4. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant. 1993;11:109-111.
5. Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Current Opinion Oncol. 1999;11:87-95.
6. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
7. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492.
8. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
9. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjugation with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622-632.
10. + cells: examination of morphology, functions, T-cell receptor rearrangement, and poreforming protein expression. Cell Immunol. 1991;136:486-495.
11. Schmidt RE, Murray C, Daley JF, et al. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986;164:351-356.
12. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
13. + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696.
14. Schmidt-Wolf IGH, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
15. + killer cells. Blood. 1995;86:3493-3499.
16. Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant. 1995; 15:33-39.
17. + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318-3327.
18. Sweeney TJ, Mailänder V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A. 1999;96:12044-12049.
19. Lu PH, Negrin RS. Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 1997;3:113-121.
20. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92:1471-1490.
21. Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1994;13:311-316.
22. Bosly A, Guillaume T, Brice P, et al. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol. 1992;20:962-968.
23. Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. 1995;16:283-288.
24. Schmidt-Wolf IGH, Lefterova P, Johnston, et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87:453-458.
25. Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609-613.
26. Pan L, Delmonte J, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.
27. Hartung T, Doecke WD, Bundschuh D, et al. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther. 1999;66:415-424.
28. Rutella S, Rumi C, Sica S, Leone G. Recombinant human granulocyte colony-stimulating factor (rHuG-CSF): effects on lymphocyte phenotype and function. J Interferon Cytokine Res. 1999;19: 989-994.
29. Reyes E, Garcia-Castro I, Esquivel F, et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer. 1999;80:229-235.
30. Leemhuis T, Wells S, Scheffold C, et al. Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma [abstract 3624]. Blood. 2000;96(suppl 1a):839a.
31. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells (CIK) from leukemic samples and its in vitro cytotoxicity against autologous leukemia [abstract 3841]. Blood. 2000; 96(suppl 1b):41b.